Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes

Research output: Contribution to journalReviewpeer-review

  1. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia

    Research output: Contribution to journalReviewpeer-review

  2. An update on the drug safety of treating erectile dysfunction

    Research output: Contribution to journalReviewpeer-review

  3. Cardiovascular safety and benefits of GLP-1 receptor agonists

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Type 2 diabetes (T2D) is a progressive disease with increasing prevalence in most countries. The majority of patients with T2D have inadequate glycaemic control, which increases the risk of diabetic complications later in life. New therapies with improved safety profiles are required to tackle the progressive nature of T2D. Areas covered: The efficacy and safety profile of IDegLira - a once-daily, fixed-ratio combination of insulin degludec and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for the treatment of T2D - has been extensively evaluated. IDegLira's phase 3 clinical trial programme builds upon the clinical programmes of its mono-components, and their cardiovascular outcomes trials. The results are described here, focusing on different patient populations and compared with alternative insulin regimens. Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects. Accordingly, co-formulations such as IDegLira are likely to be increasingly preferred over stepwise addition and titration of the individual agents in the management of T2D.

Original languageEnglish
JournalExpert Opinion on Drug Safety
Issue number3
Pages (from-to)387-396
Number of pages10
Publication statusPublished - Mar 2017

    Research areas

  • Blood Glucose, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Long-Acting, Liraglutide, Weight Gain, Journal Article, Review

ID: 52661523